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Background: The emergence of carbapenem-resistant Klebsiella pneumoniae poses a se-
rious problem to antibiotic management. We investigated the β-lactamases in a group of 
carbapenem-resistant K. pneumoniae clinical isolates from Turkey.
Methods: Thirty-seven strains of K. pneumoniae isolated from various clinical specimens 
were analyzed by antimicrobial susceptibility testing, PCR for the detection of β-lactamase 
genes, DNA sequencing, and repetitive extragenic palindronic (REP)- PCR analysis. 
Results: All 37 isolates were resistant to ampicillin, ampicillin/sulbactam, piperacillin, 
piperacillin/tazobactam, ceftazidime, cefoperazone/sulbactam, cefepime, imipenem, and 
meropenem. The lowest resistance rates were observed for colistin (2.7%), tigecycline 
(11%), and amikacin (19%). According to PCR and sequencing results, 98% (36/37) of 
strains carried at least one carbapenemase gene, with 32 (86%) carrying OXA-48 and 7 
(19%) carrying NDM-1. No other carbapenemase genes were identified. All strains car-
ried a CTX-M-2-like β-lactamase, and some carried SHV- (97%), TEM- (9%), and CTX-M-
1-like (62%) β-lactamases. Sequence analysis of blaTEM genes identified a blaTEM-166 with 
an amino acid change at position 53 (Arg53Gly) from blaTEM-1b, the first report of a muta-
tion in this region. REP-PCR analysis revealed that there were seven different clonal 
groups, and temporo-spatial links were identified within these groups. 
Conclusions: Combinations of β-lactamases were found in all strains, with the most com-
mon being OXA-48, SHV, TEM, and CTX-M-type (76% of strains). We have reported, for 
the first time, a high prevalence of the NDM-1 (19%) carbapenemase in carbapenem-re-
sistant K. pneumoniae from Turkey. These enzymes often co-exist with other β-lactamases, 
such as TEM, SHV, and CTX-M β-lactamases. 
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INTRODUCTION
Antibiotic resistance in gram-negative bacteria is a major problem 
worldwide. Resistance to β-lactam antibiotics is often mediated 
by β-lactamases, including expanded-spectrum β-lactamases 
(ESBLs), plasmid-mediated AmpC β-lactamases, and carbapen-
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emases [1]. Clinical isolates of Klebsiella pneumoniae are notori-
ous for harboring a wide range of β-lactamases and are naturally 
resistant to ampicillin and amoxycillin. β-Lactam antibiotics are 
often used in the treatment of infections caused by this bacterium 
[2]. The emergence and rapid spread of drug-resistant K. pneu-
moniae isolates has become a serious clinical challenge. 
 β-Lactamases are grouped into four classes according to their 
amino acid sequence: class A, including KPC and TEM; class B, 
the metallo-β-lactamases (MBLs) such as VIM, IMP, and NDM-
1; class C, the AmpC β-lactamases; and class D, the oxacillin-
ase (OXA)-type enzymes. All four classes of β-lactamases have 
been described in K. pneumoniae. Carbapenem resistance in K. 
pneumoniae has been reported in most countries and can be 
attributed to plasmid-mediated AmpC cephalosporinases asso-
ciated with porin modifications [3, 4], reduced outer membrane 
permeability by porin loss in combination with the production of 
an ESBL, or production of β-lactamases capable of hydrolyzing 
carbapenems (carbapenemases) [5, 6]. In Turkey, OXA-48 car-
bapenemases have been identified for a decade [5], initially de-
scribed in K. pneumoniae [7] and then in various other entero-
bacterial species [8-10]. Only recently, however, an imported 
case of NDM-1-producing K. pneumoniae has been reported in 
Turkey [11], but thus far, there have been no reports on locally 
acquired cases. 
 In this study, we aimed to characterize the β-lactamases in 
carbapenem-resistant K. pneumoniae clinical isolates from Tur-
key. These data serve an important role in understanding and 
controlling the spread of carbapenem-resistant gram-negative 
pathogens [2].
METHODS
1. Bacterial strains and antibiotic susceptibilities
The study was performed at the Bezmialem Vakif University 
Hospital in Turkey between July 2012 and March 2013. During 
the study period, all non-duplicate clinical isolates of K. pneu-
moniae obtained from inpatients that exhibited a reduced sensi-
tivity to carbapenems were characterized. Clinical isolates were 
identified by using standard microbiological procedures and VI-
TEK-2 (bioMerieux, Marcy-l’Etoile, France). The identification of 
all isolates was confirmed by 16S rDNA sequencing [12]. Sus-
ceptibility testing was performed by using the following antibiot-
ics: ampicillin, ampicillin/sulbactam, piperacillin, piperacillin/
tazobactam, cefuroxime, ceftazidime, cefoperazone/sulbactam, 
cefepime, amikacin, gentamicin, netilmicin, tobramycin, cipro-
floxacin, levofloxacin, tetracycline, trimethoprim/sulfamethoxa-
zole, imipenem, meropenem, colistin, and tigecycline. Non-sus-
ceptibility to carbapenems (imipenem and meropenem) and 
colistin during susceptibility testing was confirmed by E-test 
(bioMerieux) in accordance with the CLSI guidelines [13].
2. Detection of β-lactamase genes
K. pneumoniae strains were screened for β-lactamase-encoding 
genes by PCR. The primers used to amplify the blaSHV, blaTEM, 
blaCTX-M1, blaCTX-M2, blaGES, blaVEB, blaPER-2, blaNDM-1, blaIMP-like, blaVIM-
like, blaKPC and blaOXA-48 genes are listed in Table 1. A single reac-
tion mixture contained 5 μL genomic DNA, 20 pM of each 
primer, 10 μL reaction buffer, 3 μL 25 mM MgCl2, 200 μM 
dNTPs, and 1.5 U Go Taq Flexi Polymerase (Promega, Madison, 
WI, USA), in a final volume of 50 μL. PCR amplification was per-
formed by using standard conditions with varying annealing 
temperatures (Table 1). All PCR results were analyzed on 1% 
Table 1.  Primers used for amplication and sequencing in this 
study 





GES F:  ATGCGCTTCATTCACGCAC 863 56 [15]
R: CTATTTGTCCGTGCTCAGGA
VEB F:  ATTTCCCGATGCAAAGCGT 542 55
R: TTATTCCGGAAGTCCCTGT
PER-2 F:  ATGAATGTCATCACAAAATG 927 50
R: TCAATCCGGACTCACT
IMP F:  CATGGTTTGGTGGTTCTTGT 488 56
R: ATAATTTGGCGGACTTTGGC
VIM F:  ATTGGTCTATTTGACCGCGTC 780 58
R: TGCTACTCAACGACTGAGCG
NDM F:  TGGAATTGCCCAATATTATGC 813 54
R: TCAGCGCAGCTTGTCGGCCATGC
CTX-M- F:  GCGTGATACCACTTCACCTC 260 50 [16]
   1 group R: TGAAGTAAGTGACCAGAATC
CTX-M- F:  TGATACCACCACGCCGCTC 341 50
   2 group R: TATTGCATCAGAAACCGTGGG
TEM F:  AGTATTCAACATTTYCGTGT 860 49
R: TAATCAGTGAGGCACCTATCTC
SHV F:  ATGCGTTATATTCGCCTGTG 843 55
R: TTAGCGTTGCCAGTGCTC
OXA-48 A:  TTGGTGGCATCGATTATCGG 743 57 [7]
B: GAGCACTTCTTTTGTGATGGC
KPC A: CGTTCTTGTCTCTCATGGCC 796 52
B: CCTCGCTGTGCTTGTCATCC
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agarose containing 0.5 μg/mL ethidium bromide and subse-
quently visualized under UV light. The PCR products for NDM, 
OXA-48, and TEM β-lactamases were cloned into the pGEM-T 
Easy vector (Promega) and then sequenced by Macrogen (Am-
sterdam, The Netherlands). Sequencing results were analyzed 
by using the alignment search tool, BLAST (http://www.ncbi.
nlm.nih.gov/BLAST) [14], and the multiple sequence aligment 
program CLUSTALW2 (http://www.ebi.ac.uk/Tools/msa/clust-
alw2/). The remaining genes were evaluated according to their 
molecular size and PCR results of control groups which were 
defined as β-lactamase gene carrier bacteria in the earlier stud-
ies [7, 15, 16].
3. Repetitive Extragenic Palindronic (REP)-PCR analysis
REP-PCR was used in the genotyping of K. Pneumoniae iso-
lates. The primer pair REP 1 (5´-IIIGCGCCGICATCAGGC-3´) 
and REP 2 (5´-ACGTCTTATCAGGCCTAC-3´) was used [17], 
and the amplification reaction was performed as previously de-
scribed [15]. The amplified DNA fragments were separated by 
electrophoresis on a 1.5% agarose gel with a 1-kb DNA ladder 
(Sigma Chemicals, Ontario, Canada) as the size marker. The 
amplified DNA bands were visualized under UV light following 
ethidium bromide staining, and the banding patterns of each 
strain were captured by using an UVP bioimaging system (UVP, 
Upland, CA, USA). The REP-PCR fingerprints were analyzed by 
using the Phoretix gel analysis package (Nonlinear USA, Inc., 
Durham, NC, USA). 
RESULTS
A total of 37 K. pneumoniae isolates were identified during the 
study period and investigated. All isolates were from hospital-
acquired infections, with the majority from patients in the inten-
sive care unit (n=23), followed by patients on surgical (n=7) 
and medical wards (n=7). Of the 37 isolates, 16 (43%) were 
associated with bloodstream infections. The remaining isolates 
came from wounds (n=7, 19%), sputum (n=6, 16%), tracheal 
aspirates (n=6, 16%), cerebrospinal fluid (n=1, 3%), and a 
catheter sample (n=1, from anesthesia unit).
 According to the antibiotic susceptibility profiles, all 37 iso-
lates were resistant to ampicillin, ampicillin/sulbactam, piper-
acillin, piperacillin/tazobactam, ceftazidime, cefoperazone/sul-
bactam, cefepime, imipenem, and meropenem. The lowest lev-
els of resistance were observed for colistin (2.7%) and tigecy-
cline (11%), followed by amikacin (19%) and trimethoprim/sul-
phamethoxazole (21.6%). Of the 37 K. pneumoniae isolates, 
98% carried a carbapenemase gene. More specifically, we de-
tected OXA-48 in 32 isolates (86%) and NDM-1 in seven iso-
lates (19%). No other carbapenemases were identified within 
this group. We also observed a high prevalence of ESBLs, with 
all strains carrying a CTX-M-2 group β-lactamase and 23 iso-
lates (62%) carrying CTX-M-1. SHV-1-like and TEM-1-like 
β-lactamase were also common (97% and 92% of strains, re-
spectively). One of the blaTEM genes was identified as blaTEM-166, a 
variant of blaTEM-1b that has one amino acid change at position 
53 (Arg53Gly).
 The combination of β-lactamases relative to the site of isola-
tion and susceptibility test results are shown in Table 2. Impor-
tantly, all NDM-1-producing strains were isolated from blood. 
Furthermore, all blood isolates carried at least one carbapene-
mase (OXA-48 or NDM-1), and two (13%) carried both OXA-48 
and NDM-1. The most common combination of β-lactamases in 
a given strain was OXA-48, SHV-1-like, TEM-1-like and CTX-M-
type β-lactamase, with 76% of strains observed with this combi-
nation.
 All 37 K. pneumoniae strains were typed by REP-PCR (Fig. 
1). We observed seven predominant genotypes; the majority of 
strains (46%) clustered into genotype 6, while 19% and 16% of 
the isolates clustered in genotype 3 and 1, respectively. Of the 
17 genotype 6 isolates, 11 were isolated from the anesthesia 
Fig. 1. Repetitive extragenic palindronic (REP)-PCR profiles of 37 Klebsiella pneumoniae isolates. Seven different genotypes were ob-
served, and most isolates clustered into genotypes 1, 3, and 6.
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Table 2. Epidemiological properties of β-lactamase-producing Klebsiella pneumoniae isolates
Isolate Specimen Units Dates Treatment Outcome
Susceptible 
antibiotics
blaNDM-1 blaOXA-48 blaCTX-M1 blaCTX-M2 blaTEM blaSHV
  1 Blood AR Feb. 2013 SCF, CIP, TIG Exitus AK, TIG, CST, SXT - - + + + +
  2 Blood Gas Feb. 2013 NT Exitus AK, CN, TIG, CST, SXT - + + + - +
  3 Blood Neu Feb. 2013 TZP, SXT Other CN, TIG, CST, SXT + + + + + +
  4 Blood Neu Feb. 2013 SXT, SCF Other TIG, CST, SXT + - + + + +
  5 Blood TS Jan. 2013 NT Other AK, TIG, CST - + + + + +
  6 Sputum TS Jan. 2013 NT Other AK, CST - + + + + +
  7 Wound RO Jan. 2013 NT Other AK, CN, TIG, CST, SXT - + + + - +
  8 Sputum TS Jan. 2013 NT Other AK, TIG, CST, SXT - + + + + +
  9 Blood IM Jan. 2013 SCF, TIG Other AK, TIG, CST, SXT - + + + + +
10 Sputum RICU Jan. 2013 NT Other AK, CN, NET, TOB, TIG, 
CST, SXT
- + - + + +
11 Sputum RICU Jan. 2013 SCF, TIG Exitus AK, CN, NET, TOB, TIG, 
CST, SXT
- + - + + +
12 Wound TS Jan. 2013 CST, TIG Other AK, CST - + + + + +
13 Blood PS Jan. 2013 NT Other TIG, CST + + + + + +
14 Blood AR Jan. 2013 SCF, CST Exitus AK, CN, NET, TOB, TIG, 
CST, SXT
+ - + + + +
15 Tracheal aspirate AR Dec. 2012 SCF, TIG Exitus AK, TIG, CST, SXT - + + + + +
16 Blood AR Dec. 2012 TIG, SXT, CST Exitus AK, TIG, CST, SXT - + + + + +
17 Blood Uro Dec. 2012 NT Other AK, CN, TIG, CST, SXT + - + + + +
18 Wound GS Dec. 2012 MEM, TIG Other AK, CIP, LEV, TET, TIG, 
CST, SXT
- + + + - +
19 Tracheal aspirate AR Dec. 2012 TIG, SUL Treated CN, TIG, CST, SXT - + + + + +
20 Blood AR Dec. 2012 CST, TIG Exitus AK, TIG, CST, SXT - + + + + +
21 Catheter AR Dec. 2012 TIG, CST Exitus AK, TIG, CST, SXT - + + + + +
22 CSF AR Nov. 2012 SXT, MEM, CIP Exitus AK, TIG, CST, SXT - + + + + +
23 Sputum RICU Feb. 2013 SCF, TIG Exitus AK, CN, TIG, CST, SXT - + - + + +
24 Blood RICU Oct. 2012 TIG, SUL Exitus TIG, SXT - + - + + +
25 Blood AR Oct. 2012 TIG, SUL Exitus TIG, CST, SXT + - - + + +
26 Wound Gas Nov. 2012 NT Other AK, TET, TIG, CST, SXT - + - + + -
27 Wound AR Jul. 2012 MEM, CIP, TIG, AK Other CN, CST - + + + + +
28 Blood AR Oct. 2012 SCF, CIP Other AK, TIG, CST, SXT - + - + + +
29 Wound AR Oct. 2012 CST, SUL, TIG, AK Exitus AK, TIG, CST, SXT - + - + + +
30 Tracheal aspirate AR Nov. 2012 TIG, RIF Other AK, TIG, CST, SXT - + - + + +
31 Tracheal aspirate AR Nov. 2012 TIG, SUL, CN, 
MEM, CST 
Exitus AK, TIG, CST, SXT - + - + + +
32 Tracheal aspirate AR Nov. 2012 NT Exitus AK, TIG, CST, SXT - + - + + +
33 Blood AR Aug. 2012 CST, CSF, TIG Other AK, CN, CST - + - + + +
34 Wound Uro Jul. 2012 NT Other AK, CN, TIG, CST - + + + + +
35 Sputum AR Nov. 2012 CST, SUL, TIG Exitus AK, TIG, CST, SXT - + + + + +
36 Blood AR Sep. 2012 CST, TIG Other AK, TIG, CST - + - + + +
37 Tracheal aspirate AR Nov. 2012 NT Other AK, TIG, CST, SXT - + - + + +
Abbreviations: AR, anesthesiology and reanimation; Gas, gastroenterology; Neu, neurology; TS, thoracic surgery; RO, radiation oncology; CP, chest diseases 
polyclinic; IM, internal medicine; RICU, respiratory intensive care unit; PS, plastic surgery; Uro, urology; GS, general surgery; TZP, piperacillin/tazobactam; 
SCF, cefaperazone/sulbactam; AK, amikacin; CN, gentamicin; NET, netilmicin; TOB, tobramycin; CIP, ciprofloxacin; LEV, levofloxacin; TET, tetracycline; TIG, 
tigecycline; CST, colistin; SXT, trimethoprim/sulfamethoxazole; MEM, meropenem; SUL, sulbactam; RIF, rifampicin; CSF, cerebrospinal fluid; NT, Not treated; 
Other, the patient was transferred into a different service.
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and reanimation intensive care unit (ICU), and three were iso-
lated from the thoracic surgery unit. Of the seven genotype 3 
isolates, two were isolated from patients who were in the neurol-
ogy ward at the same time, and two were isolated from the an-
esthesia and ICU. The remaining isolates were distributed 
among other wards in the hospital over different times during 
the 9-month study period (Table 2). 
DISCUSSION
K. pneumoniae is an opportunistic pathogen that causes com-
munity- and hospital-acquired infections, such as bloodstream 
and urinary tract infections, and pneumonia [18]. Currently, 
carbapenems are the most potent antimicrobial agents used in 
the treatment of serious infections caused by multidrug-resistant 
gram-negative bacteria. However, carbapenem resistance in 
Enterobacteriaceae is emerging in Turkey [8, 9] and in other 
parts of the world [5]. Here, we described the distribution of 
major β-lactamases in a contemporary group of extensively 
drug-resistant K. pneumoniae isolates from Turkey. We observed 
that 19% of isolates carried the NDM-1 carbapenemase, and 
that all of these isolates came from bloodstream infections and 
from patients with no recent travel history, suggesting local ac-
quisition. OXA-48 carbapenemases were highly prevalent, and 
were occasionally found co-existing with NDM-1. Compounding 
these data was that over 2.7% of isolates were resistant to colis-
tin, a finding that is novel for Turkey and one with serious thera-
peutic implications. The majority of isolates came from patients 
in the ICU. 
 BLs have been reported worldwide, and their genes are often 
located on plasmids and integrons [19]. NDM is a novel MBL 
enzyme, and its variants are the latest carbapenemases to be 
recognized and reported worldwide. NDM-1 was first identified 
in a carbapenem-resistant K. pneumoniae strain from the urine 
sample of a Swedish patient of Indian origin who traveled to 
New Delhi [20]. Since then, more than 40 countries have re-
ported NDM-producing isolates [21, 22]. NDM enzymes have 
predominately been identified in Enterobacteriaceae, but have 
also been described in non-fermenters and in members of the 
Vibrionaceae family [23]. 
 Occasional community-acquired NDM-1-positive isolates have 
been reported [24], however, the overwhelming majority of iso-
lates have a nosocomial origin. In our study, all isolates were from 
nosocomial infections and all were from seriously ill patients. All 
of the NDM-1-positive isolates (n=7) were recovered from blood 
samples, and six of these were from patients in the ICU. All pa-
tients were uninfected at admission, and the organisms were iso-
lated from patients 48 hr or longer after admission.
 In Turkey, NDM-1 was first reported in 2011 in a K. pneu-
moniae isolate from a leukemia patient originally from Iraq [19]. 
Later, another team investigated NDM-1 in various carbapene-
mase-resistant gram-negative bacilli, but with negative results 
[25]. To our knowledge, the current study is the largest report 
demonstrating the presence of NDM-1 in K. pneumoniae in 
Turkey. Our results indicate that seven out of 37 (19%) car-
bapenem-resistant K. pneumonia isolates were positive for 
NDM-1, an alarming result as efforts to identify NDM-1-produc-
ing isolates in 2011 showed negative results.
 Another β-lactamase type known as OXA-48 was initially 
identified in Turkey from a K. pneumoniae isolate from Istanbul, 
and thereafter, outbreaks of OXA-48-producing K. pneumoniae 
have been described in Turkey [8-10]. To date, 11 variants of 
OXA-48 have been described [26]. Recently, the molecular 
characterization of carbapenem-resistant K. pneumoniae in a 
tertiary university hospital in Turkey was performed on 94 iso-
lates. OXA-48 and NDM-1 were produced in 91.5% and 4.3% 
of isolates, respectively [27]. In our study, OXA-48 and NDM-1 
were observed in 86% and 19% of isolates, respectively. This 
study reveals that the NDM-1 resistance gene is increasing in 
prevalence in Turkey. This increase poses a significant threat to 
Turkish infection control efforts.
 TEM or SHV β-lactamase derivatives have been the most 
prevalent ESBLs in nosocomial pathogens since the 1980s. 
However, starting from 1995, CTX-M-type ESBLs have emerged 
worldwide, including Europe, Asia, South America, and Canada 
[13, 28]. We demonstrated that these CTX-M-type ESBLs are 
also highly prevalent in multidrug-resistant K. pneumoniae in 
Turkey. In a multicenter study conducted in Turkish hospitals, 
PCR analysis was used for ESBL typing, and CTX-M was the 
most prevalent enzyme type among blood isolates (71%) of 
Escherichia coli and K. pneumonia, followed by TEM (49%) and 
SHV (47%) type enzymes [29]. 
 The CTX-M family can be classified into five major groups: 
CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25. CTX-
M-15, which belongs to the CTX-M-1 group, is the most wide-
spread of these enzymes around the world [30]. Ours is the first 
report of CTX-M-1 and CTX-M-2 in ESBL-producing carbape-
nem-resistant K. pneumoniae strains from Turkey. CTX-M-2 was 
the most prevalent β-lactamase, found in 100% of isolates, fol-
lowed by SHV (97%), TEM (92%), and CTX-M-1 (62%). The 
continued monitoring of antimicrobial resistance to β-lactams in 
each region of Turkey is urgently required to assist with the de-
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velopment of control strategies for hospital infections.
 In conclusion, our study of carbapenem-resistant, K. pneu-
moniae isolates identified the largest number of NDM-1-produc-
ing strains reported from Turkey, and revealed that these strains 
were highly resistant to a range of clinically important antibiotics. 
Furthermore, these isolates often carried the OXA-48 carbapen-
emase, and were associated with serious infections of the blood-
stream. All strains also carried multiple ESBLs, with blaCTX-M-2 be-
ing the most common. The recent emergence of NDM-1-pro-
ducing K. pneumoniae on the background of the highly preva-
lent OXA-48 and CTX-M type ESBLs is alarming for our country.
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